Response to Letter
- PMID: 39418662
- DOI: 10.1097/AOG.0000000000005741
Response to Letter
Conflict of interest statement
Financial Disclosure Neil S. Silverman reports receiving payment from Cepheid. The other authors did not report any potential conflicts of interest.
References
-
- Mok T, Nguyen AV, Kwan L, Steinberg I, Vallera C, Silverman NS, et al. Prophylactic unfractionated heparin in antepartum hospitalizations. Obstet Gynecol 2024;144:118–25. doi: 10.1097/AOG. 0000000000005599 - DOI
-
- Tepper NK, Boulet SL, Whiteman MK, Monsour M, Marchbanks PA, Hopper WC, et al. Postpartum venous thromboembolism: incidence and risk factors. Obstet Gynecol 2014;129:987–96. doi: 10.1097/AOG.0000000000000230 - DOI
-
- Krenitsky N, Friedman AM, Yu K, Gyamfi-Bannerman G, Williams-Kane J, O'Shaugnessy F, et al. Trends in venous thromboembolism and associated risk factors during delivery hospitalizations from 2000 to 2018. Obstet Gynecol 2022;139:223–34. doi: 10.1097/AOG.0000000000004648 - DOI
-
- Bistervels IM, Buchmüller A, Wiegers HMG, Ní Áinle F, Tardy B, Donnelly J, et al. Intermediate-dose versus low-dose low- molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial. Lancet 2022;400:1777–87. doi: 10.1016/S0140-6736(22)02128-6 - DOI
-
- Trujillo-Santos J, Schellong S, Falga C, Zorrilla V, Gallego P, Barrón M, et al. Low-molecular-weight or unfractionated heparin in venous thromboembolism: the influence of renal function. Am J Med 2013;126:425–34.e1. doi: 10.1016/j.amjmed.2012.09.021 - DOI
LinkOut - more resources
Full Text Sources